{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:06:41Z","timestamp":1730520401162,"version":"3.28.0"},"reference-count":31,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sun Yat-sen University Start-up Funding","award":["201603"],"award-info":[{"award-number":["201603"]}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2022A1515110503"],"award-info":[{"award-number":["2022A1515110503"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.<\/jats:p>","DOI":"10.7717\/peerj.18475","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:46:06Z","timestamp":1730450766000},"page":"e18475","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis of hepatitis B virus reactivation in newly diagnosed multiple myeloma in modern era therapy: a retrospective study"],"prefix":"10.7717","volume":"12","author":[{"given":"Weiran","family":"Lv","sequence":"first","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojin","family":"Li","sequence":"additional","affiliation":[{"name":"Hematology, Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Xu","sequence":"additional","affiliation":[{"name":"Hematology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanying","family":"Huang","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Hu","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Cui","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Song","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lezong","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyi","family":"Wu","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[{"name":"Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"10","key":"10.7717\/peerj.18475\/ref-1","doi-asserted-by":"publisher","first-page":"E611","DOI":"10.1002\/ajh.24857","article-title":"Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: a study based on the nationwide Danish multiple myeloma registry","volume":"92","author":"Andersen","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"22","key":"10.7717\/peerj.18475\/ref-2","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.7717\/peerj.18475\/ref-3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4274\/tjh.galenos.2019.2019.0103","article-title":"Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and\/or bortezomib","volume":"18, 36","author":"Atilla","year":"2019","journal-title":"Turkish Journal of Hematology"},{"issue":"10","key":"10.7717\/peerj.18475\/ref-4","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.7717\/peerj.18475\/ref-5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nature Immunology"},{"issue":"6","key":"10.7717\/peerj.18475\/ref-6","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.3892\/ol.2019.10926","article-title":"Hepatitis B virus infection and 1q21 amplification in multiple myeloma","volume":"18","author":"Guo","year":"2019","journal-title":"Oncology Letters"},{"issue":"4","key":"10.7717\/peerj.18475\/ref-7","doi-asserted-by":"publisher","first-page":"E73-4","DOI":"10.1002\/ajh.23932","article-title":"Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: astudy based on the nationwide Danish myeloma database","volume":"90","author":"Holmstrom","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"5 Suppl","key":"10.7717\/peerj.18475\/ref-8","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.7717\/peerj.18475\/ref-9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/10428194.2011.610013","article-title":"High preva-lence of hepatitis B virus infection in multiple myeloma","volume":"53","author":"Huang","year":"2012","journal-title":"Leukemia & Lymphoma"},{"issue":"8","key":"10.7717\/peerj.18475\/ref-10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/eri.11.79","article-title":"Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation","volume":"9","author":"Idilman","year":"2011","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"10.7717\/peerj.18475\/ref-11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.7717\/peerj.18475\/ref-12","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.7717\/peerj.18475\/ref-13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cld.2016.06.005","article-title":"Hepatitis B and risk of non-hepatocellular carcinoma malignancy","volume":"20","author":"Kwok","year":"2016","journal-title":"Clinics in Liver Disease"},{"issue":"11","key":"10.7717\/peerj.18475\/ref-14","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1111\/liv.12838","article-title":"Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy","volume":"35","author":"Lee","year":"2015","journal-title":"Liver International"},{"issue":"6","key":"10.7717\/peerj.18475\/ref-15","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leukemia & Lymphoma"},{"key":"10.7717\/peerj.18475\/ref-16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/annonc\/mdx694","article-title":"Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B","volume":"29","author":"Lin","year":"2017","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.7717\/peerj.18475\/ref-17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.7717\/peerj.18475\/ref-18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","article-title":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy","volume":"42","author":"Oketani","year":"2012","journal-title":"Hepatology Research"},{"issue":"1","key":"10.7717\/peerj.18475\/ref-19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinre.2011.07.018","article-title":"Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy","volume":"36","author":"Papamichalis","year":"2012","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"issue":"5","key":"10.7717\/peerj.18475\/ref-20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.7717\/peerj.18475\/ref-21","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"10.7717\/peerj.18475\/ref-22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fimmu.2020.00552","article-title":"Liver, tumor and viral hepatitis: key players in the complex balance between tolerance and immune activation","volume":"11","author":"Sallberg","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.7717\/peerj.18475\/ref-23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jceh.2015.06.002","article-title":"Emerging trends in epidemiology of hepatitis B virus infection","volume":"5","author":"Stasi","year":"2017","journal-title":"Journal of Clinical and Experimental Hepatology"},{"issue":"11","key":"10.7717\/peerj.18475\/ref-24","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/cancers11111819","article-title":"Reactivation of hepatitis B virus in patients with multiple myeloma","volume":"11","author":"Tsukune","year":"2019","journal-title":"Cancers"},{"issue":"95","key":"10.7717\/peerj.18475\/ref-25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00277-016-2742-7","article-title":"Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents\u2019 era","volume":"2016","author":"Tsukune","year":"2016","journal-title":"Annals of Hematology"},{"issue":"12","key":"10.7717\/peerj.18475\/ref-26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41408-017-0002-2","article-title":"Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan","volume":"7","author":"Tsukune","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"10.7717\/peerj.18475\/ref-27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","article-title":"Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders","volume":"68","author":"Wands","year":"1975","journal-title":"Gastroenterology"},{"issue":"2","key":"10.7717\/peerj.18475\/ref-28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12253-015-0014-9","article-title":"Chemokine expression profiles of human hepatoma cell lines mediated by hepatitis B virus X protein","volume":"22","author":"Wang","year":"2016","journal-title":"Pathology & Oncology Research"},{"issue":"4","key":"10.7717\/peerj.18475\/ref-29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.18475\/ref-30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/(ISSN)1096-9071","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"Journal of Medical Virology"},{"issue":"7","key":"10.7717\/peerj.18475\/ref-31","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"British Journal of Cancer"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/18475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18475.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18475.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:46:19Z","timestamp":1730450779000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/18475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":31,"alternative-id":["10.7717\/peerj.18475"],"URL":"https:\/\/doi.org\/10.7717\/peerj.18475","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"e18475"}}